My ePortfolio Register   

2011 St Gallen Consensus breast cancer recommendations

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.10.11
Views: 5145

Prof Richard Gelber - Dana-Farber Cancer Institute, Boston, USA; Prof Aron Goldhirsch – European Institute of Oncology, Milan

Profs Richard Gelber and Aron Goldhirsch discuss the recommendations of the 2011 St Gallen Consensus Conference. The Conference focussed on therapy recommendations for early breast cancer, based on evidence as well as clinical expertise of the international faculty.

Profs Gelber and Goldhirsch were winners of the 2011 ECCO Clinical Research Award, presented at the European Multidisciplinary Cancer Congress in Stockholm. This award is presented in recognition of outstanding international contribution to the integration of scientific research and clinical practice in the field of cancer.

Prof Richard Gelber is co-developer of two statistical methodologies designed to enhance interpretation of clinical trial data. The Quality-adjusted Time Without Symptoms of disease or Toxicity of treatment method (Q-TWiST) incorporates quality-of-life considerations into treatment comparisons, while the Subpopulation Treatment Effect Pattern Plots (STEPP) methodology facilitates interpretation of treatment effect heterogeneity derived from different patient subsets.

Prof Aron Goldhirsch was the co-developer of the Breast International Group (BIG), a non-profit organisation that facilitates breast cancer research at international level by encouraging cooperation between its members and other academic networks. Prof Goldhirsch’s research areas include new adjuvant treatments for breast cancer, definition of biological features that predict responsiveness or resistance to anti-cancer treatments, and quality-of-life-oriented approaches.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence